Home » Stocks » CytoDyn

CytoDyn, Inc. (CYDY)

Stock Price: $4.81 USD 0.02 (0.42%)
Updated Aug 10, 2020 4:00 PM EDT - End of day

Stock Price Chart

Key Info

Market Cap 2.50B
Revenue (ttm) n/a
Net Income (ttm) -81.69M
Shares Out 519.70M
EPS (ttm) -0.22
PE Ratio n/a
Forward PE 11.98
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 10, 2020
Last Price $4.81
Previous Close $4.79
Change ($) 0.02
Change (%) 0.42%
Day's Open 4.84
Day's Range 4.50 - 4.89
Day's Volume 3,749,285
52-Week Range 0.26 - 10.01

More Stats

Market Cap 2.50B
Enterprise Value 2.50B
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 519.70M
Float 430.45M
EPS (basic) -0.21
EPS (diluted) -0.22
FCF / Share -0.11
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short n/a
Short Ratio n/a
Short % of Float n/a
Beta -0.65
PE Ratio n/a
Forward PE 11.98
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio n/a
Revenue n/a
Operating Income -60.63M
Net Income -81.69M
Free Cash Flow -49.07M
Net Cash 2.93M
Net Cash / Share 0.01
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA -127.93%
ROE n/a
ROIC 425.70%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (0)

Buy 0
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: n/a

Price Target

Current: $4.81
Target: 4.00
*Average 12-month price target from 1 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Operating Income-55.85-45.92-27.33-21.18-19.60-8.11-7.99-7.46-3.70-3.30
Net Income-56.19-50.15-25.76-25.70-25.09-12.43-9.57-7.47-3.72-3.36
Shares Outstanding27217513895.4458.3846.9029.9424.6221.0819.00
Earnings Per Share-0.21-0.29-0.19-0.27-0.43-0.27-0.32-0.31-0.18-0.49
Operating Cash Flow-50.47-29.90-26.73-24.81-12.02-7.39-3.39-4.39-1.82-1.77
Capital Expenditures-0.03--0.01-0.01-0.02-0.02----
Free Cash Flow-50.49-29.90-26.74-24.82-12.04-7.41-3.40-4.39-1.83-1.77
Cash & Equivalents3.471.231.789.641.054.890.600.281.040.70
Total Debt8.24-1.06-4.272.341.990.080.160.16
Net Cash / Debt-4.771.230.729.64-3.222.55-1.390.200.880.54
Book Value-8.91-13.16-1.1010.21-10.693.92-0.22-3.97-5.01-3.22
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name CytoDyn, Inc.
Country United States
Employees 10
CEO Nader Z. Pourhassan

Stock Information

Ticker Symbol CYDY
Stock Exchange US OTC
Unique Identifier OTCMKTS: CYDY


CytoDyn Inc., a late-stage biotechnology company, focuses on the clinical development and commercialization of humanized monoclonal antibodies to treat human immunodeficiency virus (HIV) infection. Its lead product is PRO 140, a therapeutic anti-viral agent, which is in Phase IIb extension study for HIV as monotherapy, rollover study for HIV as a combination therapy, Phase IIb/III investigative trial for HIV, Phase Ib/II trial for triple-negative breast cancer, and Phase II trial for graft-versus-host disease. CytoDyn Inc. has strategic agreement with Samsung BioLogics Co. Ltd. for the clinical and commercial manufacturing of leronlimab. The company was formerly known as RexRay Corporation. CytoDyn Inc. was incorporated in 2002 and is based in Vancouver, Washington.